Home › Bladder Cancer
Bladder Cancer clinical trials recruiting in the U.S.
140 studies for Bladder Cancer are recruiting participants at sites across the United States.
Bladder cancer symptoms range from lower back pain to blood in your urine. Read about important risk factors and find a list of treatments available
Cities with the most studies
- New York City, NY36 studies
- Nashville, TN31 studies
- Houston, TX31 studies
- Dallas, TX27 studies
- Boston, MA26 studies
- Washington, DC26 studies
- Los Angeles, CA25 studies
- Baltimore, MD24 studies
- Philadelphia, PA23 studies
- Edison, NJ23 studies
- St. Louis, MO22 studies
- Chicago, IL21 studies
- Seattle, WA21 studies
- Durham, NC20 studies
- Columbus, OH19 studies
- Cleveland, OH18 studies
- Queens, NY17 studies
- Atlanta, GA16 studies
- Baldwin Park, CA14 studies
- San Antonio, TX13 studies
- San Francisco, CA13 studies
- Portland, OR13 studies
- Grand Rapids, MI12 studies
- Orange, CA12 studies
- Birmingham, AL12 studies
- Staten Island, NY12 studies
- New Rochelle, NY12 studies
- Salt Lake City, UT11 studies
- Denver, CO11 studies
- San Diego, CA11 studies
- Little Rock, AR11 studies
- Irvine, CA11 studies
- Austin, TX11 studies
- Rochester, MN11 studies
- Oklahoma City, OK11 studies
- East Norwalk, CT11 studies
- Milwaukee, WI11 studies
- Greenburgh, NY11 studies
- Sacramento, CA10 studies
- Detroit, MI10 studies
By state
- Alabama12 studies
- Alaska4 studies
- Arizona19 studies
- Arkansas16 studies
- California53 studies
- Colorado20 studies
- Connecticut10 studies
- Delaware4 studies
- District of Columbia17 studies
- Florida36 studies
- Georgia19 studies
- Idaho6 studies
- Illinois30 studies
- Indiana13 studies
- Iowa13 studies
- Kansas15 studies
- Kentucky5 studies
- Louisiana13 studies
- Maryland36 studies
- Massachusetts31 studies
- Michigan24 studies
- Minnesota23 studies
- Mississippi3 studies
- Missouri26 studies
- Montana7 studies
- Nebraska11 studies
- Nevada6 studies
- New Hampshire3 studies
- New Jersey27 studies
- New Mexico3 studies
- New York42 studies
- North Carolina26 studies
- North Dakota4 studies
- Ohio35 studies
- Oklahoma12 studies
- Oregon14 studies
- Pennsylvania29 studies
- Rhode Island4 studies
- South Carolina16 studies
- South Dakota4 studies
- Tennessee34 studies
- Texas49 studies
- Utah15 studies
- Vermont3 studies
- Virginia24 studies
- Washington25 studies
- West Virginia6 studies
- Wisconsin17 studies
- Wyoming4 studies
Recently updated studies
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07222488Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03866382Evaluation for NCI Surgery Branch Clinical Research Protocols
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT00001823Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
Recruiting
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07225205BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07869836A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07419295Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06770582Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
RecruitingObservational studyHealthy volunteers welcome
Ages 2 and older · All sexes · Updated Nov 9, 2026 · NCT00026884The Vanguard Study: Testing a New Way to Screen for Cancer
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Nov 6, 2026 · NCT06995898A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07090499A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07206225A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06465069cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Nov 4, 2026 · NCT05366881Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy
Recruiting
Ages 18 and older · Men · Updated Nov 4, 2026 · NCT05792722Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06760819FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05614739Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07660055Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07061964Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06525571Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07908979Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06963346Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT07144319En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 29, 2026 · NCT0423576418F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Oct 29, 2026 · NCT06503146From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.